title

Mendelspod Podcast

managingEditor

3
Followers
4
Plays
Mendelspod Podcast
Mendelspod Podcast

Mendelspod Podcast

managingEditor

3
Followers
4
Plays
OVERVIEWEPISODESYOU MAY ALSO LIKE

Details

About Us

Mendelspod was founded in 2011 by Theral Timpson and Ayanna Monteverdi to advance life science research, connecting people and ideas. Influenced by the thinking tools developed by Eli Goldgratt, the founders bring a unique approach to media in the life sciences. With help from our advisors around the industry, Mendelspod goes beyond quick sound bites to create a space for probing conversations and deep insight into the topics and trends which shape the industry's future and therefore our future as a species.

Latest Episodes

November 2019 with Nathan and Laura: Happy Birthday CRISPR Babies, 23andMe for Embryo Selection, and Golden Rice, Almost

The gene edited babies, Lulu and Nana, turn one. Laura Hercher says it feels like it’s been five years. Nathan says, “Happy Birthday.” Along with our genomics headline party this month, we also discuss a comment that came in from our last show which leads us to the question, can we discuss science without discussing politics? It’s Nathan, Laura and Theral for almost a full hour sifting through November’s news.

-1 s3 d ago
Comments
November 2019 with Nathan and Laura: Happy Birthday CRISPR Babies, 23andMe for Embryo Selection, and Golden Rice, Almost

Learning from the Field's Mistakes, Ancestry.com Rolls out Physician Ordered Health Testing

Just in time for Black Friday, Ancestry.com has launched new health testing. Thanksgiving week (the company calls the shopping holidays the “Turkey Five”) has been kind to what is the largest DNA testing company in the world. Back in 2017, their ancestry test competed with the Instapot for Amazon’s top sellers on the biggest shopping day of the year. To date Ancestry has sold over 15 million DNA tests.

-1 s1 w ago
Comments
Learning from the Field's Mistakes, Ancestry.com Rolls out Physician Ordered Health Testing

The Gene Edited Babies Saga - A Year Later with Hank Greely

On November 25th, 2018, the world was shocked to find out a Chinese scientist, He Jiankui, had edited the germline of twin girls-and the twins had been born. Many in the scientific community remember that Sunday afternoon well as the story broke on MIT's Tech Review, "EXCLUSIVE: Chinese scientists are creating CRISPR babies." Today’s guest can even tell you what he had for dinner that Sunday and just what was his reaction. "Holy Shit!"

-1 s1 w ago
Comments
The Gene Edited Babies Saga - A Year Later with Hank Greely

Improving Quantitative Evidence for Genetic Tests: Carlos Araya, Invitae

Warning: the first part of this story can sound quite typical. Three co-founders with backgrounds in genomics and AI found a Stanford spinout. Their goal: to bring the tools of AI and computational modeling to unlock the medical secrets of the genome and deliver those to patients. They call this company, Jungla—Spanish for “jungle”—naming not only their adventure, but the whole problem. Then things get interesting.

-1 s3 w ago
Comments
Improving Quantitative Evidence for Genetic Tests: Carlos Araya, Invitae

The Meteoric Rise of Twist Bioscience and the Wild Demand for DNA: Emily Leproust, CEO

In 2013 Twist Bioscience was a newcomer to a market that most of us thought was saturated, cornered, commoditized—that of synthetic DNA. But Emily Leproust and her co-founders saw something different. They saw "a big market with unhappy customers.” Today, with a radically disruptive technology, they are market dominant. Twist is a publicly traded company whose stock has doubled already once since they IPOd last year. Imagine, a DNA synthesis company going public! And then seeing their stock perform so well. This is tricky for the most hyped of tech or biotech startups.

-1 sNOV 8
Comments
The Meteoric Rise of Twist Bioscience and the Wild Demand for DNA: Emily Leproust, CEO

October 2019 Review with Nathan and Laura: Prime Editing, Vertex Win, and ASHG

Our Halloween show this year summarizing October’s genomics news has more tricks and treats than spooks and scares. It’s Nathan and Laura back to sift through a big month of happenings from the cool CRISPR upgrade to Inscripta’s bold move in gene editing to Ancestry.com’s shift into health testing. It’s all here, right now, on Mendelspod.

-1 sNOV 2
Comments
October 2019 Review with Nathan and Laura: Prime Editing, Vertex Win, and ASHG

Should We Increase Panel Testing for All Breast Cancer Patients?

It’s a hot question in the field today. Recently several studies arguing for increased testing for all breast cancer patients have been published in leading oncology journals. Peter Beitsch is a breast cancer surgeon in Dallas Texas and co-author of one such study in the Journal of Clinical Oncology. He says that NCCN guidelines were created when tests were much more expensive and in an outdated context and that many patients are going under-diagnosed today.

-1 sOCT 25
Comments
Should We Increase Panel Testing for All Breast Cancer Patients?

Genomics Going from a Passive to an Active Science: John Stuelpnagel on the “Write” Revolution

Not many people have had quite the same view on the genomics revolution as John Stuelpnagel. He co-founded Illumina, Ariosa, and Fabric Genomics (formerly Omicia). And he’s the Chairman of Fabric, 10X Genomics, and Inscripta. And not all had the foresight John did that biology would turn out to be so complex. John is our guest today to preview and describe what he calls the new “writing” phase of genomics, which he says is already underway.

-1 sOCT 22
Comments
Genomics Going from a Passive to an Active Science: John Stuelpnagel on the “Write” Revolution

Why Isn’t Personalized Medicine Being Mentioned by the Presidential Contenders? Ed Abrahams on Drug Pricing, Genetic Testing, and the State of the Industry in 2019

Ed Abrahams has a message for Nancy Pelosi about HR 3. That’s the new bill in the House to reduce drug pricing. Ed is the President of the Personalized Medicine Coalition, an advocacy organization in Washington representing our industry which will soon announce a new caucus in congress devoted to personalized medicine. Ed joins us today and says to Pelosi, there’s a better way, a more American way to reduce drug costs.

-1 sOCT 16
Comments
Why Isn’t Personalized Medicine Being Mentioned by the Presidential Contenders? Ed Abrahams on Drug Pricing, Genetic Testing, and the State of the Industry in 2019

Karen Miga on the Next Era of Genomics

"Welcome to the era of T2T genomics,” tweeted UCSC’s Karen Miga on August 16th of this year. Then she linked to a paper on bioRxiv that begins: "After nearly two decades of improvements, the current human reference genome (GRCh38) is the most accurate and complete vertebrate genome ever produced. However, no one chromosome has been finished end to end, and hundreds of unresolved gaps persist.”

-1 sOCT 8
Comments
Karen Miga on the Next Era of Genomics

Latest Episodes

November 2019 with Nathan and Laura: Happy Birthday CRISPR Babies, 23andMe for Embryo Selection, and Golden Rice, Almost

The gene edited babies, Lulu and Nana, turn one. Laura Hercher says it feels like it’s been five years. Nathan says, “Happy Birthday.” Along with our genomics headline party this month, we also discuss a comment that came in from our last show which leads us to the question, can we discuss science without discussing politics? It’s Nathan, Laura and Theral for almost a full hour sifting through November’s news.

-1 s3 d ago
Comments
November 2019 with Nathan and Laura: Happy Birthday CRISPR Babies, 23andMe for Embryo Selection, and Golden Rice, Almost

Learning from the Field's Mistakes, Ancestry.com Rolls out Physician Ordered Health Testing

Just in time for Black Friday, Ancestry.com has launched new health testing. Thanksgiving week (the company calls the shopping holidays the “Turkey Five”) has been kind to what is the largest DNA testing company in the world. Back in 2017, their ancestry test competed with the Instapot for Amazon’s top sellers on the biggest shopping day of the year. To date Ancestry has sold over 15 million DNA tests.

-1 s1 w ago
Comments
Learning from the Field's Mistakes, Ancestry.com Rolls out Physician Ordered Health Testing

The Gene Edited Babies Saga - A Year Later with Hank Greely

On November 25th, 2018, the world was shocked to find out a Chinese scientist, He Jiankui, had edited the germline of twin girls-and the twins had been born. Many in the scientific community remember that Sunday afternoon well as the story broke on MIT's Tech Review, "EXCLUSIVE: Chinese scientists are creating CRISPR babies." Today’s guest can even tell you what he had for dinner that Sunday and just what was his reaction. "Holy Shit!"

-1 s1 w ago
Comments
The Gene Edited Babies Saga - A Year Later with Hank Greely

Improving Quantitative Evidence for Genetic Tests: Carlos Araya, Invitae

Warning: the first part of this story can sound quite typical. Three co-founders with backgrounds in genomics and AI found a Stanford spinout. Their goal: to bring the tools of AI and computational modeling to unlock the medical secrets of the genome and deliver those to patients. They call this company, Jungla—Spanish for “jungle”—naming not only their adventure, but the whole problem. Then things get interesting.

-1 s3 w ago
Comments
Improving Quantitative Evidence for Genetic Tests: Carlos Araya, Invitae

The Meteoric Rise of Twist Bioscience and the Wild Demand for DNA: Emily Leproust, CEO

In 2013 Twist Bioscience was a newcomer to a market that most of us thought was saturated, cornered, commoditized—that of synthetic DNA. But Emily Leproust and her co-founders saw something different. They saw "a big market with unhappy customers.” Today, with a radically disruptive technology, they are market dominant. Twist is a publicly traded company whose stock has doubled already once since they IPOd last year. Imagine, a DNA synthesis company going public! And then seeing their stock perform so well. This is tricky for the most hyped of tech or biotech startups.

-1 sNOV 8
Comments
The Meteoric Rise of Twist Bioscience and the Wild Demand for DNA: Emily Leproust, CEO

October 2019 Review with Nathan and Laura: Prime Editing, Vertex Win, and ASHG

Our Halloween show this year summarizing October’s genomics news has more tricks and treats than spooks and scares. It’s Nathan and Laura back to sift through a big month of happenings from the cool CRISPR upgrade to Inscripta’s bold move in gene editing to Ancestry.com’s shift into health testing. It’s all here, right now, on Mendelspod.

-1 sNOV 2
Comments
October 2019 Review with Nathan and Laura: Prime Editing, Vertex Win, and ASHG

Should We Increase Panel Testing for All Breast Cancer Patients?

It’s a hot question in the field today. Recently several studies arguing for increased testing for all breast cancer patients have been published in leading oncology journals. Peter Beitsch is a breast cancer surgeon in Dallas Texas and co-author of one such study in the Journal of Clinical Oncology. He says that NCCN guidelines were created when tests were much more expensive and in an outdated context and that many patients are going under-diagnosed today.

-1 sOCT 25
Comments
Should We Increase Panel Testing for All Breast Cancer Patients?

Genomics Going from a Passive to an Active Science: John Stuelpnagel on the “Write” Revolution

Not many people have had quite the same view on the genomics revolution as John Stuelpnagel. He co-founded Illumina, Ariosa, and Fabric Genomics (formerly Omicia). And he’s the Chairman of Fabric, 10X Genomics, and Inscripta. And not all had the foresight John did that biology would turn out to be so complex. John is our guest today to preview and describe what he calls the new “writing” phase of genomics, which he says is already underway.

-1 sOCT 22
Comments
Genomics Going from a Passive to an Active Science: John Stuelpnagel on the “Write” Revolution

Why Isn’t Personalized Medicine Being Mentioned by the Presidential Contenders? Ed Abrahams on Drug Pricing, Genetic Testing, and the State of the Industry in 2019

Ed Abrahams has a message for Nancy Pelosi about HR 3. That’s the new bill in the House to reduce drug pricing. Ed is the President of the Personalized Medicine Coalition, an advocacy organization in Washington representing our industry which will soon announce a new caucus in congress devoted to personalized medicine. Ed joins us today and says to Pelosi, there’s a better way, a more American way to reduce drug costs.

-1 sOCT 16
Comments
Why Isn’t Personalized Medicine Being Mentioned by the Presidential Contenders? Ed Abrahams on Drug Pricing, Genetic Testing, and the State of the Industry in 2019

Karen Miga on the Next Era of Genomics

"Welcome to the era of T2T genomics,” tweeted UCSC’s Karen Miga on August 16th of this year. Then she linked to a paper on bioRxiv that begins: "After nearly two decades of improvements, the current human reference genome (GRCh38) is the most accurate and complete vertebrate genome ever produced. However, no one chromosome has been finished end to end, and hundreds of unresolved gaps persist.”

-1 sOCT 8
Comments
Karen Miga on the Next Era of Genomics
hmly
himalayaプレミアムへようこそ聴き放題のオーディオブックをお楽しみください。